Advertisement

Tumor Biology

, Volume 36, Issue 2, pp 991–996 | Cite as

Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer

  • Massimiliano Bissolati
  • Maria Teresa Sandri
  • Giovanni Burtulo
  • Laura Zorzino
  • Gianpaolo Balzano
  • Marco Braga
Research Article

Abstract

Pancreatic cancer patients underwent surgical resection often present distant metastases early after surgery. Detection of circulating tumor cells (CTCs) has been correlated to a worse oncological outcome in patients with advanced pancreatic cancer. The objective of this pilot study is to investigate the possible prognostic role of CTCs in patients undergoing surgery for pancreatic cancer. In 20 patients undergoing pancreatic resection, 10 mL blood sample was collected intraoperatively from both systemic circulation (SC) and portal vein (PV). Blood sample was analyzed for CTCs with CellSearch® system. All patients underwent an oncologic follow-up for at least 3 years, quarterly. CTCs were detected in nine (45 %) patients: five patients had CTCs in PV only, three patients in both SC and PV, and one patient in SC only. CTC-positive and CTC-negative patients were similar for demographics and cancer stage pattern. No significant differences were found in both overall and disease-free survival between CTC-positive and CTC-negative patients. At 3-year follow-up, portal vein CTC-positive patients presented a higher rate of liver metastases than CTC-negative patients (53 vs. 8 %, p = 0.038). CTCs were found in 45 % of the patients. No correlation between CTCs and survival was found. The presence of CTCs in portal vein has been associated to higher rate of liver metastases after surgery.

Keywords

Circulating tumor cells Pancreatic cancer Surgery Portal vein Liver metastases 

Notes

Conflicts of interest

None

References

  1. 1.
    Baschnagel A, Shah C, Margolis J, Nadeau L, Stein J, Jury R, et al. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine. Int J Radiat Oncol Biol Phys. 2012;83:e331–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Miller RC, Iott MJ, Corsini MM. Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium. Int J Radiat Oncol Biol Phys. 2009;75:364–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Hattangadi JA, Hong TS, Yeap BY, Mamon HJ. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer. 2009;115:3640–50.CrossRefPubMedGoogle Scholar
  4. 4.
    Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009;35:600–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006;33:S9–14.CrossRefPubMedGoogle Scholar
  8. 8.
    Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Groot Koerkamp B, Rahbari NN, Büchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013;20:2156–65.CrossRefPubMedGoogle Scholar
  11. 11.
    de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Doyen J, Alix-Panabières C, Hofman P, Parks SK, Chamorey E, Naman H, et al. Circulating tumor cells in prostate cancer: a potential surrogate marker of survival. Crit Rev Oncol Hematol. 2012;81:241–56.CrossRefPubMedGoogle Scholar
  13. 13.
    Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol. 2009;175:808–16.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29:1556–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008;14:7004–10.CrossRefPubMedGoogle Scholar
  16. 16.
    Bidard FC, Belin L, Delaloge S, Lerebours F, Ngo C, Reyal F, et al. Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the REMAGUS02 study. Int J Breast Cancer. 2013;2013:130470.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Karhade M, Hall C, Mishra P, Anderson A, Kuerer H, Bedrosian I, et al. Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2014;147:325–33.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, SUCCESS Study Group, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106(5). doi: 10.1093/jnci/dju066
  19. 19.
    Gazzaniga P, de Berardinis E, Raimondi C, Gradilone A, Busetto GM, De Falco E, et al. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int J Cancer. 2014;135:1978–82.CrossRefPubMedGoogle Scholar
  20. 20.
    Thorsteinsson M, Jess P. The clinical significance of circulating tumor cells in non-metastatic colorectal cancer—a review. Eur J Surg Oncol. 2011;37:459–65.CrossRefPubMedGoogle Scholar
  21. 21.
    Urtishak S, Alpaugh RK, Weiner LM, Swaby RF. Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development. Biomark Med. 2008;2:137–45.CrossRefPubMedGoogle Scholar
  22. 22.
    Uchikura K, Takao S, Nakajo A, Miyazono F, Nakashima S, Tokuda K, et al. Intraoperative molecular detection of circulating tumor cells by reverse transcription-polymerase chain reaction in patients with biliary-pancreatic cancer is associated with hematogenous metastasis. Ann Surg Oncol. 2002;9:364–70.CrossRefPubMedGoogle Scholar
  23. 23.
    Soeth E, Grigoleit U, Moellmann B, Röder C, Schniewind B, Kremer B, et al. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol. 2005;131:669–76.CrossRefPubMedGoogle Scholar
  24. 24.
    Sergeant G, Roskams T, van Pelt J, Houtmeyers F, Aerts R, Topal B. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma. BMC Cancer. 2011;11:47.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kurihara T, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Tsuji S, et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg. 2008;15:189–95.CrossRefPubMedGoogle Scholar
  26. 26.
    Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol. 2013;24:2057–61.CrossRefPubMedGoogle Scholar
  27. 27.
    Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2012;106:508–16.CrossRefPubMedGoogle Scholar
  28. 28.
    Han L, Chen W, Zhao Q. Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Tumour Biol. 2014;35(3):2473–80.CrossRefPubMedGoogle Scholar
  29. 29.
    Kagan M, Howard D, Bendele T, Rao C, Terstappen L. Circulating tumor cells as cancer markers: a sample preparation and analysis system. Tumor markers physiology, pathobiology, technology and applications. Washington D.C.: AACC; 2003. p. 495–8. chapter 52.Google Scholar
  30. 30.
    Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–904.CrossRefPubMedGoogle Scholar
  31. 31.
    de Albuquerque A, Kubisch I, Breier G, Stamminger G, Fersis N, Eichler A, et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology. 2012;82:3–10.CrossRefPubMedGoogle Scholar
  32. 32.
    Sergeant G, van Eijsden R, Roskams T, Van Duppen V, Topal B. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery. BMC Cancer. 2012;12:527.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Zhong W, Chen W, Zhang D, Sun J, Li Y, Zhang J, et al. CXCL12/CXCR4 axis plays pivotal roles in the organ-specific metastasis of pancreatic adenocarcinoma: a clinical study. Exp Ther Med. 2012;4:363–9.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Tjensvoll K, Nordgård O, Smaaland R. Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. Int J Cancer. 2014;134:1–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Massimiliano Bissolati
    • 1
  • Maria Teresa Sandri
    • 2
  • Giovanni Burtulo
    • 1
  • Laura Zorzino
    • 2
  • Gianpaolo Balzano
    • 1
  • Marco Braga
    • 1
  1. 1.Department of SurgeryVita-Salute San Raffaele UniversityMilanItaly
  2. 2.Division of Laboratory MedicineEuropean Institute of OncologyMilanItaly

Personalised recommendations